BACKGROUND: Black race is associated with prostate cancer (PC) diagnosis and poor outcome. Previously, the authors reported that black men undergoing radical prostatectomy (RP) in equal-access hospitals had an increased risk of biochemical disease recurrence (BCR), but recurrences were equally aggressive as those occurring in white men. The authors examined the association between race and long-term outcomes after RP. METHODS: Data regarding 1665 black men (37%) and 2791 white men (63%) undergoing RP were analyzed. Using Cox models, the authors tested the association between race and BCR, BCR with a prostate-specific antigen (PSA) doubling time <9 months (aggressive disease recurrence), metastases, PC-specific death, and overall death. RESULTS: At a median follow-up of 102 months, 1566 men (35%) developed BCR, 217 men (5%) experienced aggressive disease recurrence, 193 men (4%) developed metastases, and 1207 men (27%) had died, 107 of whom (2%) died of PC. White men were older and had a lower preoperative PSA level, a lower biopsy and pathological grade group, and more capsular penetration but less seminal vesicle invasion and positive surgical margins versus black men (all P<.05). Black men were found to have a more recent surgery year (P<.001). On univariable analysis, black race was associated with increased BCR (P 5 .003) and reduced overall death (P 5 .017). On multivariable analysis, black race was not found to be associated with BCR (hazard ratio [HR], 1.07; P 5 .26), aggressive recurrence (HR, 1.14; P 5 .42), metastasis (HR, 1.24; P 5 .21), PC-specific death (HR, 1.03; P 5 .91), or overall death (HR, 1.03; P 5 .67). CONCLUSIONS: Among men undergoing RP at equal-access centers, although black men were found to have an increased risk of BCR, they had similar risks of aggressive disease recurrence, metastasis, and PC-specific death compared with white men, and the risk of BCR was found to be similar after controlling for risk parameters. Longer follow-up is needed to confirm these findings. Cancer 2017;123:4199-206.
INTRODUCTION
Black men in the United States have the highest incidence of and mortality from prostate cancer (PC) compared with other races. 1 The reasons for this remain controversial, but are likely multifactorial. 2 There are clear racial differences in socioeconomic status, which some have argued are a major contributor to the poorer outcomes noted among black men. 3, 4 Although socioeconomic differences undoubtedly are important, there also are racial differences in genetics that could contribute to this observation. 5, 6 Further evaluating the contribution of each of these factors remains an important endeavor.
A different approach to studying race and PC is to study men from equal-access centers. As such, the Veterans Affairs (VA) health system, the largest health care delivery system in the United States, is ideally poised for such a study due to its equal-access nature and the high percentage of black men. Using the Shared Equal Access Regional Cancer Hospital (SEARCH) database, we previously studied men undergoing radical prostatectomy (RP) and found that black race was associated with an increased risk of biochemical disease recurrence (BCR) but similar prostate-specific antigen (PSA) doubling times (PSADT) at disease recurrence. 7 Given that PSADT is correlated with the risk of PC-specific death, 8 this would suggest that, among men in equal-access medical centers who all were treated with surgery, race would not impact PC death. However, at the time of our prior analyses, long-term cancer control data were not available. Indeed, to the best of our knowledge, there are only a limited number of studies regarding racial differences in long-term outcomes among men treated with RP, which were limited by either being small and including only black men (222 patients), 9 only examining older men (those aged >65 years), not controlling for PSA values, 10 or having a short follow-up (median follow-up of 4 years). 11 With continued followup, we now have long-term cancer control data (metastasis and PC death) and overall survival (OS) data. Herein, we report the early findings of the association between race and long-term outcomes after RP from SEARCH, which to our knowledge is the largest study to date examining race and the risk of metastases, PC-specific death, and OS after RP in black men with equal access to care.
MATERIALS AND METHODS

Patient Population
After obtaining Institutional Review Board approval, we combined data from patients undergoing RP between 1988 and 2016 at VA hospitals in West Los Angeles, San Diego, and Palo Alto in California; Augusta, Georgia; and Durham and Asheville in North Carolina into the SEARCH database. 12 Patients treated with preoperative androgen deprivation or radiotherapy were excluded from the current study. Of 5515 patients, we excluded men with missing data for race or those whose race was classified as other (199 patients) and men with missing data regarding biopsy grade group (487 patients), pathological grade group (48 patients), preoperative PSA level (79 patients), surgical margin status (39 patients), capsular penetration (93 patients), seminal vesicle invasion (19 patients), or no PSA or overall follow-up (95 patients), resulting in a study population of 4456 patients.
Study Outcomes
BCR was defined as a single PSA measurement >0.2 ng/mL, 2 concentrations at 0.2 ng/mL, or secondary treatment for an elevated postoperative PSA level. A total of 84 white men (3.0%) and 58 black men (3.5%) received adjuvant treatment for an undetectable PSA level and were censored as having nonrecurrent disease at the time of adjuvant treatment (P 5 .43, chi-square test). For BCR, patients were censored at the time of last known PSA. For patients who received secondary treatments after BCR, we included all data without censoring because this was considered salvage and not adjuvant therapy. A total of 1147 men received salvage treatment after BCR, 487 of whom were black (29.3%) and 660 of whom were white (23.7%) (P<.001, chi-square test).
PSADT at the time of disease recurrence was calculated by dividing the natural log of 2 (0.693) by the slope of the linear regression line of the natural log of PSA over time. To calculate the PSADT, patients must have had 2 PSA values, separated by 3 months, within 2 years after disease recurrence. All PSA values obtained within the first 2 years after disease recurrence were used. For patients initiating salvage hormonal therapy or radiotherapy within this time, only values before salvage therapy were used. Patients with a PSADT <0 months (ie, no increase/decline in PSA) or >120 months (178 patients) were assigned a PSADT of 120 months for ease of calculations.
We a priori defined aggressive disease recurrence as a recurrence with a PSADT <9 months, based on the high PC-specific mortality risk reported in a prior study. 8 Patients without disease recurrence were censored as not having an aggressive recurrence at time of last PSA. Patients with BCR and a PSADT 9 months were censored as not having an aggressive disease recurrence at the time of recurrence because these men were considered to be at a low risk of PC death in a prior study. 8 Patients with disease recurrence but incalculable PSADT (439 patients) were unclassifiable and were excluded from aggressive recurrence analyses.
Metastases were identified typically by bone scan or computed tomography imaging performed as per the discretion of the treating clinician. Equivocal scans were considered negative because they do not change treatment management unless confirmed as positive by a secondary imaging modality or biopsy. Patients without metastases were censored either at the time of death or at last known contact.
The date and cause of death were ascertained via VA electronic medical records. Patients were censored at the date of last known contact. Men who died with metastatic, progressive, castrate-resistant PC without another obvious cause of death were considered to have died of PC.
Statistical Analysis
We explored differences in clinicopathological characteristics by race using the rank sum test for continuous variables and the chi-square test for categorical variables. Time to BCR, aggressive disease recurrence, metastases, PCspecific death, and OS were compared between races using Kaplan-Meier plots and log-rank tests. To test differences in disease progression for black versus white patients, we used a Cox proportional hazards model adjusted for age (continuous), year of surgery (continuous), treatment center (categorical), biopsy grade group Original Article (ordinal: 1, 2, 3, 4, and 5), and preoperative PSA level (continuous, logarithmically transformed). In a separate model, in addition to preoperative characteristics, we further adjusted for the pathological characteristics of surgical margins, capsular penetration, seminal vesicle invasion, lymph nodes (categorical: positive, negative, and not performed), and pathological grade group (1, 2, 3, 4, and 5). In the latter model, we did not adjust for biopsy grade group given the inclusion of pathological grade group. Because data regarding body mass index (BMI) were missing for 345 men (8%) and there was no statistically significant difference between the BMIs of black and white patients (Table 1) , we explored whether including these men altered the results of the current study. Specifically, analyses were conducted among all men as well as only those men with available data regarding BMI adjusting for BMI. When limited to those patients with BMI data, the results were unchanged. We concluded that BMI was not a confounder in the current analysis and therefore we included men with missing BMI data and did not adjust for BMI.
All statistical analyses were performed using Stata statistical software (version 14.2; StataCorp LLC, College Station, Texas).
RESULTS
A total of 37% of the men in the current study were black (1665 men). Black men were younger at the time of surgery (P<.001), underwent RP more recently (P<.001), had higher PSA values (P<.001), were in a higher biopsy grade group (P<.001) and pathological grade group (P<.001), and were less likely to have capsular penetration (P 5 .022), but were more likely to have positive surgical margins (P<.001) and seminal vesicle invasion (P 5 .023) ( Table 1) .
Biochemical Disease Recurrence
The mean and median PSA follow-up periods for men without BCR were 80 months and 70 months, respectively. During this time, 1566 men (35%) developed BCR: 1244 due to an elevated PSA and 322 due to secondary treatment for a rising PSA but one that was below the recurrence threshold. The median time from surgery to disease recurrence among men with BCR was 18.0 months and the median time from surgery to secondary treatment was 13.4 months. Overall, black men were significantly more likely to develop BCR (P 5 .003, logrank test) (Fig. 1) . When men who developed disease recurrence due to secondary treatment were excluded, the Table 2 ).
Metastasis
The mean and median overall follow-up periods among those patients without metastases were 103 months and 93 months, respectively. During that time, 193 men (4.3%) developed metastases. Overall, black men had a risk of metastases similar to that of white men (P 5 .42, log-rank test) (Fig. 3) . This lack of an association between race and metastases remained unchanged after adjusting for multiple clinical or clinical and pathological characteristics (HR, Table 2) .
PC-Specific and OS
The mean and median overall follow-up periods among those patients still alive at the time of last follow-up were 102 months and 91 months, respectively. During that time, 1207 men (27%) died, 107 of whom (2%) died of PC. Overall, black race was not found to be related to PCspecific death (P 5 .410, log-rank test) (Fig. 4) , but was found to be associated with an improved OS risk (P 5 .017, log-rank test) (Fig. 5) Table 2) .
DISCUSSION
Black men have increased incidence of and mortality from PC compared with white men. To the best of our knowledge, the exact reasons for this are not clear. One key issue relates to access to care. If black men have the same access to care and receive the same treatment, regardless of socioeconomic status and other disease-related factors, can they expect similar outcomes? Herein, we addressed a subgroup of men diagnosed with PC who had equal access to care within the VA system and elected to undergo RP. A previous study of this population from our group found that black men undergoing RP had a slightly higher risk of disease recurrence, although the PSADT at the time of recurrence (a measure of disease aggressiveness) was similar in black and white men. To our knowledge, only limited data are available regarding endpoints of critical importance in this population, including the risk of metastases, PC-specific survival, and OS after RP. To address this, we queried the SEARCH database, a database from multiple equal-access VA centers consisting of 4456 patients (37% of whom were black and 63% of whom were white) treated with RP during the PSA era. We found that black men had higher recurrence rates and correspondingly higher rates of undergoing salvage therapy. However, when adjusting for disease severity, we found no difference in the risk of disease recurrence, aggressive disease recurrence, metastases, PC-specific survival, and OS between the groups. These data suggest that with equal access to care, black men still present with worse disease resulting in higher recurrence rates, but when this worse disease at the time of diagnosis is accounted for, black men can expect equally effective and long-term results after RP, although longer follow-up is needed to confirm these findings. To our knowledge, the current study is the largest study to date examining race and the risk of metastases, PC-specific death, and OS after RP in black men with equal access to care. A prior study of 222 intermediaterisk and low-risk patients (65% of whom were black) from the VA NY Harbor Health Care System in New York City who were treated with RP found that PCspecific survival did not differ by race. 9 Although this finding is in agreement with the results of the current study, these findings were based on 4 metastatic events and 2 PC deaths, thereby preventing any meaningful conclusions. Similarly, the results of the current study are consistent with limited data from non-equal-access medical centers as well. An analysis of men who underwent RP in the Surveillance, Epidemiology, and End ResultsMedicare database between 1991 and 2009 found no racial differences in PC-specific or all-cause mortality. 10 This study was limited in that it only examined older men (those aged >65 years); did not control for PSA values; and controlled for tumor grade using the American Joint Committee on Cancer grading system, in which 98% of patients had grade 2 or 3 versus our approach of using the commonly used grade grouping. Finally, data from John Hopkins, which included 15,993 white men (91%) and 1634 black men (9%) undergoing RP from 1992 through 2013, found that long-term outcomes, including metastasis-free survival and PC-specific survival, did not differ by race. 11 However, these results were limited by a 4-year median follow-up. Thus, to the best of our knowledge, the preponderance of the literature to date concludes that when disease is detected early enough for a patient to be a surgical candidate and treated aggressively with RP, black men have long-term outcomes similar to those of white men.
It is interesting to note that both the study from the VA NY Harbor Health Care System and that from Johns Hopkins found that despite no differences in PC death risk, black men were more likely to experience a disease recurrence. Indeed, we found similar results in the current study, albeit this was not significant after multivariable analysis. Moreover, multiple other studies have found similar results, [13] [14] [15] although some found no differences in the rate of disease recurrence by race. 16, 17 In trying to put these 2 disparate pieces of information together (higher recurrence rates but similar long-term outcomes), we propose several possible explanations. First, black men received secondary treatments at a higher rate, which may have resulted in improved long-term survival and thus matched the survival of white men. Second, black men may respond better to secondary treatments such as salvage radiotherapy or hormonal therapy. There are some data that suggest that tumors in black men are more hormonally driven (ie, higher expression of the androgen receptor), 18, 19 which in theory may make them more hormonally sensitive. Third, BCR is not a surrogate for PC death because many men with disease recurrence will not die of their disease. 8 Thus, perhaps recurrences in black men, although higher in number, are less aggressive on the whole, leading to an overall equal number of PC deaths. This is supported by the finding in the current study that black men were no more likely to develop an aggressive disease recurrence. Finally, all the studies examining PC death after RP (including the current study) are underpowered to detect modest associations between race and PC death. Although the HRs for PC death actually were <1 in the current study, suggesting there is no evidence of even a slightly increased risk, we cannot confidently exclude a modest positive association. Thus, further studies with longer follow-up and more patients are needed.
Despite the finding that long-term outcomes after RP are similar, black men continue to present at earlier ages and with more aggressive disease, thereby leading to an overall increased risk of PC death at the population level. 20 To the best of our knowledge, the reasons for black men having an increased incidence of and mortality from PC at the population level remain unclear and are likely multifactorial. 21 However, the fact that, even when diagnosed early and treated equally in an equal-access medical center, black men presented at younger ages and had higher rates of disease recurrence suggests potential biological differences by race. At the molecular level, possible causes include genetics; differences in androgen levels and androgen receptor biology; dietary factors; and lifestyle factors affecting PC carcinogenesis pathways, such as smoking. 2 Powell et al 22 recently found no difference between black and white men with regard to PC incidence or extent at autopsy, and suggested that specific factors in black men somehow trigger the transformation from latent to aggressive PC. Recent data have suggested that aggressive PC in black men may be related to the presence of the Broad11934905 risk allele, which is unique to men of African descent and is present on chromosome 8q24 (a known PC risk loci). 23 Moreover, we found that several aggressive PC markers, including Ki-67, androgen receptor, and alpha-methylacyl-CoA racemase (AMACR), were more highly expressed among black men. 18 Finally, differences between black and white men with regard to inflammatory gene expression in tumors have been noted. 24, 25 Indeed, there are genetic differences in inflammatory-related genes between races: black men have lower expression of DARC, a Duffy antigen/chemokine receptor for chemokines such as CXCL1 and CXCL8, on endothelial cells and erythrocytes. 26 Loss of DARC is hypothesized to be selected for in men of African ancestry because it leads to malaria resistance. With regard to inflammation, DARC acts as a sink for cytokines and thus loss of DARC leads to higher systemic cytokines. 27 All this evidence further supports the hypothesis that PC may be biologically different in black men compared with white men.
The current study has several limitations. The number of events at the various endpoints (metastasis, OS, and PC-specific survival) was modest. Thus, we were relatively underpowered to detect these later events and therefore we cannot exclude a weak to modest association between race and long-term outcomes. Likewise, given the long natural history of PC and our modest mean follow-up of approximately 8.5 years, it is possible that the results of the current study may potentially change with longer follow-up and larger sample sizes. The current study only evaluated men undergoing RP, and thus represents a selection bias of men who are healthy enough to undergo surgery and excludes those men who present with metastatic disease, who typically are not offered surgery. Future studies should address progression endpoints in black men undergoing other treatments such as radiotherapy. Nonetheless, our approach in analyzing only surgical patients creates a more homogenous cohort wherein we can better question whether equal men, when treated equally, have equal outcomes. Moreover, to the best of our knowledge, the current study still represents the largest to date evaluating metastasis and death in black men with equal access to care undergoing RP. Further studies from other institutions are required to verify our findings.
The results of the current study found that, among black and white men undergoing RP at the multiple equal-access centers of the SEARCH database, black men were at an increased risk of BCR in univariate but not multivariable analysis, a finding that is consistent with our prior results. 10 However, black men did not appear to be at an increased risk of aggressive disease recurrence or the longer-term outcomes of metastasis, PC-specific death, or overall death compared with white men. Because the number of events was small, even longer follow-up will be required to confirm these findings. Whether similar results will be observed in non-equal-access centers remains to be determined.
